In 2014, BELLUS Health entered into a development and license agreement with AMO Pharma Limited (AMO Pharma) for the worldwide rights to AMO-01 (formerly TLN-4601) for the treatment of neurologic and psychiatric disorders in return for royalties on sales and revenue sharing. TLN-4601 was acquired by BELLUS Health as part of the Thallion Pharmaceutical Inc. (Thallion) acquisition in August 2013.
AMO Pharma is a private company focused on the treatment of central nervous system and neuromuscular diseases. AMO Pharma is expected to initiate a Phase 2 study in the first half of 2017 on patients with Fragile X Syndrome, the most common inherited cause of autism and intellectual disabilities, affecting approximately 1 in 4,000 males and 1 in 8,000 females. Symptoms range in severity and can include intellectual disabilities, attention deficit and hyperactivity, anxiety and seizures. There are currently no approved drugs indicated for the treatment of Fragile X Syndrome.